Cargando…

False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial

PURPOSE: Readers need to be informed about potential pitfalls of [(68)Ga]Ga-PSMA-11 PET interpretation. METHODS: Here we report [(68)Ga]Ga-PSMA-11 PET findings discordant with the histopathology/composite reference standard in a recently published prospective trial on 635 patients with biochemically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fendler, Wolfgang P., Calais, Jeremie, Eiber, Matthias, Simko, Jeffrey P., Kurhanewicz, John, Santos, Romelyn Delos, Feng, Felix Y., Reiter, Robert E., Rettig, Matthew B., Nickols, Nicholas G., Kishan, Amar U., Slavik, Roger, Carroll, Peter R., Lawhn-Heath, Courtney, Herrmann, Ken, Czernin, Johannes, Hope, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835157/ https://www.ncbi.nlm.nih.gov/pubmed/32808077 http://dx.doi.org/10.1007/s00259-020-04945-1

Ejemplares similares

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
por: Calais, Jeremie, et al.
Publicado: (2021)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer
por: Meyer, Catherine, et al.
Publicado: (2023)

Evaluation of SUV normalized by lean body mass (SUL) in (68)Ga-PSMA11 PET/CT: a bi-centric analysis
por: Gafita, Andrei, et al.
Publicado: (2019)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
por: Gafita, Andrei, et al.
Publicado: (2022)

PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Pitfalls in PSMA imaging: [(18)F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
por: Feuerecker, B., et al.
Publicado: (2021)

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study
por: Sonni, Ida, et al.
Publicado: (2023)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting
por: Johnsson, Kerstin, et al.
Publicado: (2021)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

PSMA PET imaging in the diagnosis and management of prostate cancer
por: Houshmand, Sina, et al.
Publicado: (2023)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement
por: Duriseti, Sai, et al.
Publicado: (2023)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Urine cytology: Pitfall due to a “remnant” lesion
por: Chaump, Michael, et al.
Publicado: (2015)

Mask R-CNN assisted 2.5D object detection pipeline of (68)Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging
por: Xu, Di, et al.
Publicado: (2023)

Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction
por: Lawhn-Heath, Courtney, et al.
Publicado: (2018)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
por: Kuo, Phillip H., et al.
Publicado: (2023)

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
por: Schottelius, Margret, et al.
Publicado: (2015)

The Impact of (18)F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
por: Fendler, Wolfgang P., et al.
Publicado: (2023)

A Comprehensive Assessment of (68)Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
por: Abghari-Gerst, Monica, et al.
Publicado: (2022)

Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT
por: Kane, Nathanael, et al.
Publicado: (2022)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
por: Topoozian, Mark, et al.
Publicado: (2023)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models
por: Sun, Jinny, et al.
Publicado: (2021)

Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study
por: Murthy, Vishnu, et al.
Publicado: (2023)

Hyperpolarized in vivo pH imaging reveals grade-dependent acidification in prostate cancer
por: Korenchan, David E., et al.
Publicado: (2019)

(68)Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality
por: Murthy, Vishnu, et al.
Publicado: (2020)

Pitfalls in Gallium-68 PSMA PET/CT Interpretation—A Pictorial Review
por: Shetty, Deepa, et al.
Publicado: (2018)

Elevated Tumor Lactate and Efflux in High-grade Prostate Cancer demonstrated by Hyperpolarized (13)C Magnetic Resonance Spectroscopy of Prostate Tissue Slice Cultures
por: Sriram, Renuka, et al.
Publicado: (2020)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
por: Holzgreve, Adrien, et al.
Publicado: (2023)

A rare case of polyostotic fibrous dysplasia detected on (18)F-rhPSMA-7 PET/CT
por: Wang, Hui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_heaj820etd4rodeslvvcaeg21t